Quarterly report pursuant to Section 13 or 15(d)

Equity

v3.24.1.u1
Equity
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Equity

Note 5 - Equity 

 

In August 2020, the Company entered into the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, “JonesTrading”, pursuant to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand™ Sales Agreement (the “A&R Sales Agreement”) with JonesTrading and B. Riley Securities, Inc. (“B. Riley”). The A&R Sales Agreement modifies the original Capital on Demand™ Sales Agreement to include B. Riley Securities as an additional sales agent thereunder. Shares of common stock are offered pursuant to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the “Prior Shelf Registration Statement”). On August 11, 2023, the Company filed a new registration statement on Form S-3 (File No. 333-273911), which registration statement was amended on February 2, 2024, and declared effective on February 5, 2024, to replace the Prior Shelf Registration Statement, including a base prospectus which covers the offering, issuance and sale of up to $500 million of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering, issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued and sold under the Amended Sales Agreement.

 

For the three months ended March 31, 2024, the Company sold 1.8 million shares of common stock, resulting in gross proceeds of $15.0 million and net proceeds of $14.7 million. For the three months ended March 31, 2023, the Company sold 0.1 million shares of common stock, resulting in gross proceeds and net proceeds of $0.8 million. 

 

Stock Options

 

The following is a summary of stock option activity for the three months ended March 31, 2024:

 

(in thousands, except for per-share amounts)   Number of Shares     Weighted
Average
Exercise
Price ($)		     Weighted
Average
Remaining
Contractual
Term
(in years)		     Aggregate
Intrinsic
Value		  
Outstanding, January 1, 2024     5,445     $ 6.80       8.70     $ 373  
Granted    
-
      
-
                  
Exercised     (10 )     7.39                  
Cancelled     (14 )     5.76                  
Outstanding, March 31, 2024     5,421       6.80       8.49       12,545  
                                 
Exercisable, March 31, 2024     1,797       9.84       7.32       3,144  

 

During the three months ended March 31, 2024, the Company did not grant any stock options. The fair values of all options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at March 31, 2024 was $13.2 million related to unvested options, which is expected to be expensed over a weighted average of 3.2 years. During the three months ended March 31, 2024 and 2023, the Company recorded compensation expense related to stock options of $1.2 million and $0.8 million, respectively.

 

Restricted Stock Units

 

The following is a summary of restricted stock unit activity for the three months ended March 31, 2024:

 

(in thousands, except for per-share amount)   RSUs     Weighted
Average
Grant date Fair Value
Per Share ($)		  
Outstanding, January 1, 2024     305       5.89  
Granted    
-
      
-
  
Vested    
-
      
-
  
Outstanding, March 31, 2024     305       5.89  

 

The RSUs vest at the earliest of a change of control event, the termination of the recipient’s continuous service status for any reason other than by the Company for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.8 million, was determined based on the stock prices on the dates of the grants and is being recognized over three years. The unrecognized compensation expense at March 31, 2024 of $0.8 million is expected to be expensed over 1.4 years. During the three months ended March 31, 2024 and 2023, the Company recorded compensation expense related to RSUs of $0.1 million and $0.2 million, respectively.

 

Warrants

 

Following is a summary of warrant activity for the three months ended March 31, 2024:

 

(in thousands, except for per-share amounts)   Number of Shares     Weighted
Average
Exercise
Price ($)		     Weighted
Average
Remaining
Contractual
Term
(in years)		     Aggregate
Intrinsic
Value		  
Outstanding, January 1, 2024     1,442     $ 16.42       0.34     $
-
  
Granted    
-
      
-
                  
Expired     (3 )     166.50                  
Outstanding, March 31, 2024     1,439     $ 16.08       0.09     $
-
  
                                 
Exercisable, March 31, 2024     1,436     $ 15.58       0.08     $
-